Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D

NCT00145327 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00145327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00145327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 3-year, Double-blind Extension to CZOL446H2301 to Evaluate the Long-term Safety and Efficacy of Zoledronic Acid in the Treatment of Osteoporosis in Postmenopausal Women Taking Calcium and Vitamin D
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
November 30, 2009
Enrollment
2,456 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis